vs
Side-by-side financial comparison of ONTO INNOVATION INC. (ONTO) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
ONTO INNOVATION INC. is the larger business by last-quarter revenue ($218.2M vs $177.4M, roughly 1.2× Pacira BioSciences, Inc.). ONTO INNOVATION INC. runs the higher net margin — 12.9% vs 1.6%, a 11.3% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -13.5%). Over the past eight quarters, ONTO INNOVATION INC.'s revenue compounded faster (2.6% CAGR vs -0.2%).
Onto Innovation Inc. is an American semiconductor company formed in 2019 from the merger of Rudolph Technologies, Inc. and Nanometrics Incorporated. It is a provider of process and process control equipment and software for microelectronic manufacturing industries.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ONTO vs PCRX — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $218.2M | $177.4M |
| Net Profit | $28.2M | $2.9M |
| Gross Margin | 50.7% | — |
| Operating Margin | 10.9% | 3.9% |
| Net Margin | 12.9% | 1.6% |
| Revenue YoY | -13.5% | 5.0% |
| Net Profit YoY | -46.8% | — |
| EPS (diluted) | $0.57 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | — | $196.9M | ||
| Q3 25 | $218.2M | $179.5M | ||
| Q2 25 | $253.6M | $181.1M | ||
| Q1 25 | $266.6M | $168.9M | ||
| Q4 24 | $263.9M | $187.3M | ||
| Q3 24 | $252.2M | $168.6M | ||
| Q2 24 | $242.3M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $28.2M | $5.4M | ||
| Q2 25 | $33.9M | $-4.8M | ||
| Q1 25 | $64.1M | $4.8M | ||
| Q4 24 | $48.8M | — | ||
| Q3 24 | $53.1M | $-143.5M | ||
| Q2 24 | $52.9M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | 50.7% | 80.9% | ||
| Q2 25 | 48.2% | 77.4% | ||
| Q1 25 | 53.7% | 79.7% | ||
| Q4 24 | 50.2% | 78.7% | ||
| Q3 24 | 54.1% | 76.9% | ||
| Q2 24 | 52.9% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | 10.9% | 3.5% | ||
| Q2 25 | 12.7% | 4.7% | ||
| Q1 25 | 23.7% | 1.2% | ||
| Q4 24 | 16.1% | 13.2% | ||
| Q3 24 | 21.0% | -82.8% | ||
| Q2 24 | 20.2% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | 12.9% | 3.0% | ||
| Q2 25 | 13.4% | -2.7% | ||
| Q1 25 | 24.0% | 2.8% | ||
| Q4 24 | 18.5% | — | ||
| Q3 24 | 21.0% | -85.1% | ||
| Q2 24 | 21.9% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | — | $0.05 | ||
| Q3 25 | $0.57 | $0.12 | ||
| Q2 25 | $0.69 | $-0.11 | ||
| Q1 25 | $1.30 | $0.10 | ||
| Q4 24 | $0.98 | $0.38 | ||
| Q3 24 | $1.07 | $-3.11 | ||
| Q2 24 | $1.07 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $603.1M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.0B | $653.9M |
| Total Assets | $2.2B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | $603.1M | $246.3M | ||
| Q2 25 | $217.5M | $445.9M | ||
| Q1 25 | $203.7M | $493.6M | ||
| Q4 24 | $212.9M | $484.6M | ||
| Q3 24 | $188.7M | $453.8M | ||
| Q2 24 | $172.6M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | — | $693.1M | ||
| Q3 25 | $2.0B | $727.2M | ||
| Q2 25 | $2.0B | $757.8M | ||
| Q1 25 | $1.9B | $798.5M | ||
| Q4 24 | $1.9B | $778.3M | ||
| Q3 24 | $1.9B | $749.6M | ||
| Q2 24 | $1.8B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | $2.2B | $1.3B | ||
| Q2 25 | $2.1B | $1.5B | ||
| Q1 25 | $2.1B | $1.6B | ||
| Q4 24 | $2.1B | $1.6B | ||
| Q3 24 | $2.1B | $1.5B | ||
| Q2 24 | $2.0B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $83.4M | — |
| Free Cash FlowOCF − Capex | $82.0M | — |
| FCF MarginFCF / Revenue | 37.6% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | 2.95× | — |
| TTM Free Cash FlowTrailing 4 quarters | $261.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $43.7M | ||
| Q3 25 | $83.4M | $60.8M | ||
| Q2 25 | $57.9M | $12.0M | ||
| Q1 25 | $92.0M | $35.5M | ||
| Q4 24 | $56.0M | $33.1M | ||
| Q3 24 | $67.2M | $53.9M | ||
| Q2 24 | $65.3M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | $82.0M | $57.0M | ||
| Q2 25 | $44.2M | $9.3M | ||
| Q1 25 | $83.7M | $26.9M | ||
| Q4 24 | $51.4M | $31.0M | ||
| Q3 24 | $59.2M | $49.8M | ||
| Q2 24 | $53.0M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | 37.6% | 31.7% | ||
| Q2 25 | 17.4% | 5.1% | ||
| Q1 25 | 31.4% | 15.9% | ||
| Q4 24 | 19.5% | 16.6% | ||
| Q3 24 | 23.5% | 29.6% | ||
| Q2 24 | 21.9% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | 0.6% | 2.2% | ||
| Q2 25 | 5.4% | 1.5% | ||
| Q1 25 | 3.1% | 5.1% | ||
| Q4 24 | 1.8% | 1.1% | ||
| Q3 24 | 3.2% | 2.4% | ||
| Q2 24 | 5.1% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.95× | 11.20× | ||
| Q2 25 | 1.71× | — | ||
| Q1 25 | 1.44× | 7.37× | ||
| Q4 24 | 1.15× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | 1.23× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ONTO
| Systems And Software Revenue | $173.8M | 80% |
| Parts Revenue | $23.9M | 11% |
| Service Revenue | $20.5M | 9% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
